Precision targeting of METTL3 via bone-homing bisphosphonate-modified PLGA nanoparticles mitigates osteoporotic bone loss through m

Qing An, Yi Xie, Chang Xu, Qun Xu, Fanshuang Kong

Department of osteology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, China.Department of osteology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, China. · pubmed

Paper

Abstract

Osteoporosis (OP), characterized by progressive bone loss, is closely linked to ferroptosis-induced senescence of bone marrow mesenchymal stem cells (BMSCs). N6-methyladenosine (m

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that targeting METTL3 with bisphosphonate-modified nanoparticles can reduce osteoporotic bone loss by addressing ferroptosis-induced senescence in BMSCs. This research is relevant as it explores a potential intervention that targets cellular senescence, a key mechanism associated with aging and age-related bone loss.

Author of this paper? Send a correction.